Monoclonal antibodies are being used to treat a variety of autoimmune disorders, including multiple sclerosis, neuromuscular diseases and rheumatoid arthritis, but neurological adverse effects have been reported in a substantial number of patients. Bosch et al. describe the characteristics, pathogenesis and outcomes of neurological disorders associated with monoclonal antibody therapy, and make recommendations regarding their management.
- Xavier Bosch
- Albert Saiz
- Manuel Ramos-Casals